BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 Nyakale N, Filippi L, Aldous C, Sathekge M. Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma. Cancers 2023;15:1975. [DOI: 10.3390/cancers15071975] [Reference Citation Analysis]
2 Fernández-Ferreira R, Savage-Leyva R, Durán-Guerrero LF, Carranza-Sevilla MDR, Zamorano-Vazquez C, Monroy-Godínez CF, Hernández-Ramírez GR, Torres-Zazueta JM, Ceron-Ibarra E, Dorantes-Heredia R. Mandibular Metastasis as the First Manifestation of Hepatocellular Carcinoma: A Case Report. Case Rep Oncol 2023;16:88-95. [PMID: 36820214 DOI: 10.1159/000529182] [Reference Citation Analysis]
3 Jacobs G, Boyle DA, El-Serag HB, Lewandowski RJ, Stein SM, Lazure P, McFadden P. Clinical care in hepatocellular carcinoma: A mixed methods assessment of experiences and challenges of oncology professionals. Cancer Med 2023;12:3670-83. [PMID: 36106593 DOI: 10.1002/cam4.5216] [Reference Citation Analysis]
4 Maciak M, Konior M, Wawszczak D, Majewska A, Brodaczewska K, Piasecki P, Narloch J, Sady M, Olszewski J, Gajewski Z, Kieda C, Dziel T, Iller E. Physical properties and biological impact of 90Y microspheres prepared by sol-gel method for liver radioembolization. Radiation Physics and Chemistry 2023;202:110506. [DOI: 10.1016/j.radphyschem.2022.110506] [Reference Citation Analysis]
5 Lengyel CG. Mechanisms of Resistance to Immunotherapies in Cancer. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_335-1] [Reference Citation Analysis]
6 Guven DC, Erul E, Sahin TK, Dizdar O, Yalcin S, Sahin IH. The benefit of immunotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Future Oncology 2022. [DOI: 10.2217/fon-2022-0642] [Reference Citation Analysis]
7 Santarsiero A, Pappalardo I, Rosa GM, Pisano I, Superchi S, Convertini P, Todisco S, Scafato P, Infantino V. Mitochondrial Role in Intrinsic Apoptosis Induced by a New Synthesized Chalcone in Hepatocellular Carcinoma Cells. Biomedicines 2022;10. [PMID: 36551876 DOI: 10.3390/biomedicines10123120] [Reference Citation Analysis]
8 Martínez MJ, Andreu AB, Barbini L. Cytotoxic activity of Solanum tuberosum polyphenolic extracts in human hepatocarcinoma cells is mediated by apoptosis and autophagy. Journal of Food Science 2022. [DOI: 10.1111/1750-3841.16366] [Reference Citation Analysis]
9 Shkaraburov AS, Rudenko DN, Vaiman EF, Soboleva OM, Zakharova YV. Asymptomatic Hepatocellular Carcinoma (Clinical Case). Kreativnaâ hirurgiâ i onkologiâ 2022;12:256-260. [DOI: 10.24060/2076-3093-2022-12-3-256-260] [Reference Citation Analysis]
10 Li J, Nie Y, Jia W, Wu W, Song W, Li Y. Effect of Tertiary Lymphoid Structures on Prognosis of Patients with Hepatocellular Carcinoma and Preliminary Exploration of Its Formation Mechanism. Cancers (Basel) 2022;14:5157. [PMID: 36291944 DOI: 10.3390/cancers14205157] [Reference Citation Analysis]
11 Luo Y, Xu Z, Wang Q, Zhao J. The Crosstalk Between CTNNB1 Mutation and M2 Macrophages Contribute to Hepatocellular Carcinoma Suppressive Immune Microenvironment.. [DOI: 10.21203/rs.3.rs-2176946/v1] [Reference Citation Analysis]
12 Kouroumalis E, Tsomidis I, Voumvouraki A. Is There a Place for Somatostatin Analogues for the Systemic Treatment of Hepatocellular Carcinoma in the Immunotherapy Era? Livers 2022;2:315-335. [DOI: 10.3390/livers2040024] [Reference Citation Analysis]
13 Zhang C, Yang Y, Wang K, Chen M, Lu M, Hu C, Du X, Xing B, Liu X, Zhang J. The Systematic Analyses of RING Finger Gene Signature for Predicting the Prognosis of Patients with Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/2466006] [Reference Citation Analysis]
14 Mossenta M, Busato D, Dal Bo M, Macor P, Toffoli G. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. Int J Mol Sci 2022;23:10038. [PMID: 36077433 DOI: 10.3390/ijms231710038] [Reference Citation Analysis]
15 Mohamed EE, Abdel-moneim A, Ahmed OM, Zoheir KM, Eldin ZE, El-shahawy AA. Anticancer activity of a novel naringin‒dextrin nanoformula: Preparation, characterization, and in vitro induction of apoptosis in human hepatocellular carcinoma cells by inducing ROS generation, DNA fragmentation, and cell cycle arrest. Journal of Drug Delivery Science and Technology 2022;75:103677. [DOI: 10.1016/j.jddst.2022.103677] [Reference Citation Analysis]
16 Bang S, Jee S, Son H, Cha H, Sim J, Kim Y, Park H, Myung J, Kim H, Paik S. Clinicopathological Implications of ASAP1 Expression in Hepatocellular Carcinoma. Pathol Oncol Res 2022;28:1610635. [DOI: 10.3389/pore.2022.1610635] [Reference Citation Analysis]
17 Sun Y, Guan X, Zhang T, Li Y, Shi H, Chitakunye AT, Hong H, Zhang S, Zhu Q, Cai L. Regulation of the sensitivity of hepatocarcinoma cells by ORMDL3, to sorafenib by autophagy. Med Oncol 2022;39:159. [PMID: 35972600 DOI: 10.1007/s12032-022-01767-z] [Reference Citation Analysis]
18 Yin Z, Chen D, Liang S, Li X. . JHC 2022;Volume 9:929-46. [DOI: 10.2147/jhc.s357313] [Reference Citation Analysis]
19 Ghenea CȘ, Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, Romania, Dumitrescu Ș, Negoiță LM, Mihăilă M, Albu LC, Constantinescu G, Department of Oncology, Fundeni Clinical Institute, Bucharest, Romania, Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, Romania, Center of Internal Medicine, Fundeni Clinical Institute, Bucharest, Romania, Center of Internal Medicine, Fundeni Clinical Institute, Bucharest, Romania, Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, Romania, 4University of Medicine. Real-World Single-Center Clinical Data on Sorafenib in Patients with Unresectable Hepatocellular Carcinoma. JMRO 2022;2:17-25. [DOI: 10.53011/jmro.2022.01.03] [Reference Citation Analysis]
20 Radmilović-radjenović M, Bošković N, Sabo M, Radjenović B. An Analysis of Microwave Ablation Parameters for Treatment of Liver Tumors from the 3D-IRCADb-01 Database. Biomedicines 2022;10:1569. [DOI: 10.3390/biomedicines10071569] [Reference Citation Analysis]
21 Hou W, Bridgeman B, Malnassy G, Ding X, Cotler SJ, Dhanarajan A, Qiu W. Integrin subunit beta 8 contributes to lenvatinib resistance in HCC. Hepatol Commun 2022;6:1786-802. [PMID: 35238496 DOI: 10.1002/hep4.1928] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Bai Y, Hu X, Ren Z, Hisai T, Yusa W, Weng L, Shiba S, Takase T. A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma. Future Oncol 2022;18:2413-24. [PMID: 35674480 DOI: 10.2217/fon-2022-0229] [Reference Citation Analysis]
23 Chang H, Lee SH. Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: a systemic review and meta-analysis. Clin Exp Med 2022. [PMID: 35737170 DOI: 10.1007/s10238-022-00842-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Sas Z, Cendrowicz E, Weinhäuser I, Rygiel TP. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. Int J Mol Sci 2022;23:3778. [PMID: 35409139 DOI: 10.3390/ijms23073778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
25 Chen Y, Yang C, Chung C, Ho C, Chen W, Chien W. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study. Hepatol Int. [DOI: 10.1007/s12072-021-10281-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
26 Lima Cavalcanti ID. Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer. Chemotherapy Protocols and Infusion Sequence 2022. [DOI: 10.1007/978-3-031-10839-6_5] [Reference Citation Analysis]
27 Markakis GE, Koulouris A, Tampaki M, Cholongitas E, Deutsch M, Papatheodoridis GV, Koskinas J. The changing epidemiology of hepatocellular carcinoma in Greece. Ann Gastroenterol 2022;35:88-94. [PMID: 34987294 DOI: 10.20524/aog.2021.0680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Tanaka H, Horioka K, Hasebe T, Sawada K, Nakajima S, Konishi H, Isozaki S, Goto M, Fujii Y, Kamikokura Y, Ogawa K, Nishikawa Y. Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: A novel therapy exploiting tumor‐platelet interactions. Intl Journal of Cancer. [DOI: 10.1002/ijc.33915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
30 Radjenović B, Sabo M, Šoltes L, Prnova M, Čičak P, Radmilović-Radjenović M. On Efficacy of Microwave Ablation in the Thermal Treatment of an Early-Stage Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5784. [PMID: 34830937 DOI: 10.3390/cancers13225784] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
31 Shahrbaf MA, Goudarzi K, Karimi Taheri K, Keshavarz Alikhani H, Noori M, Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran., Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran, Research and Development Department, Royan Stem Cell Technology Co, Tehran, Iran. Faculty of Sciences, University of Science and Culture, Tehran, Iran. Chimeric antigen receptor (CAR) T cell therapy in hepatocellular carcinoma; a review of recent advances. Mod Med Lab J 2021;4:19-27. [DOI: 10.30699/mmlj17.4.2.19] [Reference Citation Analysis]
32 Chen JG, Zhu J, Zhang YH, Chen YS, Ding LL, Chen HZ, Shen AG, Wang GR. Liver Cancer Survival: A Real World Observation of 45 Years with 32,556 Cases. J Hepatocell Carcinoma 2021;8:1023-34. [PMID: 34513745 DOI: 10.2147/JHC.S321346] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
33 Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs 2021;:1-9. [PMID: 34429006 DOI: 10.1080/13543784.2021.1972969] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 27.0] [Reference Citation Analysis]